Publications by authors named "G Tillotson"
Article Synopsis
- This paper talks about how depression, problems with gut bacteria (called dysbiosis), and C. difficile infections are connected, which they call "The 3 Ds."
- It points out that more people are getting depressed, which can be made worse by medicines like antidepressants that might change the bacteria in our guts.
- Finally, it discusses new treatments, like special bacteria products, that could help people who keep getting C. difficile infections.
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately 30% of the US population has a CYP2C19 no-function allele that reduces the effectiveness of clopidogrel, but not prasugrel or ticagrelor, after PCI. We have shown improved outcomes with the integration of CYP2C19 genotyping into clinical care to guide the selection of prasugrel or ticagrelor in CYP2C19 no-function allele carriers.
View Article and Find Full Text PDFComment on: Community-acquired pneumonia: a US perspective on the guideline gap.
J Antimicrob Chemother
August 2024
Microbiota restoration therapies for recurrent infection reach an important new milestone.
Therap Adv Gastroenterol
May 2024
Article Synopsis
- Microbiota restoration therapy is a new treatment for a recurring infection called rCDI, using special products made from healthy gut bacteria.
- Two main products have been approved: RBX2660 (REBYOTA™) and SER-109 (VOWST™), both aimed at preventing rCDI and helping doctors understand their differences.
- Research shows these treatments are safe and effective, and they help restore a healthy balance of gut bacteria, which is important for fighting infections.
Microbiota-Based Live Biotherapeutic Products for Infection- The Devil is in the Details.
Infect Drug Resist
February 2024
infection (CDI) remains a significant contributor to healthcare costs and morbidity due to high rates of recurrence. Currently, available antibiotic treatment strategies further disrupt the fecal microbiome and do not address the alterations in commensal flora (dysbiosis) that set the stage for CDI. Advances in microbiome-based research have resulted in the development of new agents, classified as live biotherapeutic products (LBPs), for preventing recurrent CDI (rCDI) by restoring eubiosis.
View Article and Find Full Text PDF